The U.S. Food and Drug Administration has approved the use of Eli Lilly and Company’s (NYSE: LLY) insulin, Lyumjev, with an insulin pump. The FDA approved the drug itself in June 2020 as a rapid-acting mealtime treatment to help control blood sugar levels.
This latest approval allows for the insulin to be administered through a continuous subcutaneous insulin infusion using a pump. The approval covers 100 units/ml for adults with type 1 and type 2 diabetes.
“Insulin pumps are an important delivery option for people with diabetes – many of whom struggle with high postmeal blood sugar levels,” said Dr. Leonard Glass, vice president of Medical Affairs, Lilly. “The expansion of the Lyumjev label to include use in an insulin pump provides a new and important choice for people with diabetes. It is an exciting development for pump users seeking to manage their blood sugar levels and reduce postmeal spikes.”
Lyumjev is available in the U.S. and in several global markets, including Japan and the European Union, where it is also approved for use in insulin pumps.